DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases.
For more information please visit www.diamedica.com.
For more information please visit www.diamedica.com.
Location: United States, Minnesota, Minneapolis
Employees: 11-50
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | Hermed Cap... | hermedcapi... |
Mentions in press and media 3
| Date | Title | Description |
| 08.03.2021 | DiaMedica Therapeutics to Participate at Upcoming Investor Conferences | MINNEAPOLIS--(BUSINESS WIRE)--Mar 8, 2021-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that t... |
| 03.03.2021 | DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021 | MINNEAPOLIS--(BUSINESS WIRE)--Mar 3, 2021-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that i... |
| - | DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting | MINNEAPOLIS--(BUSINESS WIRE)--Feb 25, 2021-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that Dr. Harry Alcorn, its... |